1241377-74-1Relevant articles and documents
Discovery of potent macrocyclic HCV NS5A inhibitors
Yu, Wensheng,Vibulbhan, Bancha,Rosenblum, Stuart B.,Martin, Gregory S.,Vellekoop, A. Samuel,Holst, Christian L.,Coburn, Craig A.,Wong, Michael,Selyutin, Oleg,Ji, Tao,Zhong, Bin,Hu, Bin,Chen, Lei,Dwyer, Michael P.,Jiang, Yueheng,Nair, Anilkumar G.,Tong, Ling,Zeng, Qingbei,Agrawal, Sony,Carr, Donna,Rokosz, Laura,Liu, Rong,Curry, Stephanie,McMonagle, Patricia,Ingravallo, Paul,Lahser, Fred,Asante-Appiah, Ernest,Fells, James,Kozlowski, Joseph A.
, p. 3793 - 3799 (2016)
HCV NS5A inhibitors have demonstrated impressive in vitro virologic profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed-dose combination (FDC) regimen for the treatment of HCV infection. Merck's effort in this area identified MK-4882 and MK-8325 as early development leads. Herein, we describe the discovery of potent macrocyclic NS5A inhibitors bearing the MK-8325 or MK-4882 core structure.
COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS AND PHARMACEUTICAL USES THEREOF
-
Paragraph 00248; 00252, (2016/09/26)
The invention provides compounds as hepatitis C virus inhibitors and pharmaceutical uses thereof. Specifically, the invention provides compounds of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a
FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
-
Paragraph 0336; 0337, (2015/12/08)
no abstract published
